Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Deepak L Bhatt (Brigham and Women's Hospital, Boston, MA, US) discuss the SOLOIST-WHF study. Host, Dr Van Spall asks how does sotagliflozin compare to drugs within the SGLT2i class. Dr Bhatt discusses the eligibility criteria and baseline characteristics. They talk about the impact of the COVID-19 on the study design. Dr Van Spall asks about the results subgroup analysis with focus on to the augmented effect on patients with preserved ejection fraction.
Recorded remotely from Hamilton and Boston, 2020.
Recording Editor: Natascha Wienand
Editor: Mirjam Boros